Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2013 and publicly traded on NASDAQ under the ticker SPRO, it focuses on developing treatments for rare diseases and multidrug-resistant bacterial infections.
The company maintains an exclusive licensing agreement with GSK, excluding certain Asian territories, for tebipenem pivoxil (Utebzi), an oral carbapenem antibiotic. In June 2026, the US FDA approved Utebzi for complicated urinary tract infections, including pyelonephritis, in adults with limited or no alternative oral options. GSK holds an approximately 15.9% ownership stake in Spero.
Official website: sperotherapeutics.com
